(State or other jurisdiction of incorporation or organization) | (Commission File No.) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Emerging growth company |
Exhibit No. | Description | |||||||
99.1 | ||||||||
104 | The Cover Page from this Current Report on Form 8-K, Interactive Data File (formatted as Inline XBRL) |
PRIVIA HEALTH GROUP, INC. | |||||||||||
Date: February 27, 2024 | By: | /s/ David Mountcastle | |||||||||
Name: David Mountcastle | |||||||||||
Title: Executive Vice President, Chief Financial Officer and Authorized Officer |
![]() | Exhibit 99.1 | |||||||||||||
For the Years Ended December 31, | ||||||||||||||||||||
($ in millions, except per share amounts) | 2023 | 2022 | Change (%) | |||||||||||||||||
Total revenue | $ | 1,657.7 | $ | 1,356.7 | 22.2 | % | ||||||||||||||
Gross profit | $ | 353.8 | $ | 302.3 | 17.0 | % | ||||||||||||||
Operating income (loss) | $ | 20.6 | $ | (19.1) | nm | |||||||||||||||
Net income (loss) a | $ | 23.1 | $ | (8.6) | nm | |||||||||||||||
Non-GAAP adjusted net income b | $ | 81.5 | $ | 63.7 | 27.9 | % | ||||||||||||||
Net income (loss) per share | $ | 0.20 | $ | (0.08) | nm | |||||||||||||||
Non-GAAP adjusted net income per share | $ | 0.64 | $ | 0.52 | 23.1 | % | ||||||||||||||
a.Net income for full-year 2023 included $37.1 million in non-cash stock compensation expense and $7.9 million in legal, non-recurring, and other expenses. Net loss for full-year 2022 included $67.4 million in non-cash stock compensation expense and $8.0 million in legal, non-recurring, and other expenses. b.Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release. |
For the Years Ended December 31, | ||||||||||||||||||||
($ in millions) | 2023 | 2022 | Change (%) | |||||||||||||||||
Implemented Providers | 4,305 | 3,606 | 19.4 | % | ||||||||||||||||
Value-Based Care Attributed Lives | 1,120,000 | 856,000 | 30.8 | % | ||||||||||||||||
Practice Collections | $ | 2,839.0 | $ | 2,424.1 | 17.1 | % | ||||||||||||||
Care Margin | $ | 359.2 | $ | 305.6 | 17.5 | % | ||||||||||||||
Platform Contribution | $ | 173.5 | $ | 148.5 | 16.8 | % | ||||||||||||||
Adjusted EBITDA | $ | 72.2 | $ | 60.9 | 18.7 | % | ||||||||||||||
Initial FY 2023 Guidance c | Updated FY 2023 Guidance | FY 2023 | |||||||||||||||||||||
($ in millions) | Low | High | at January 8, 2024 | Actual | |||||||||||||||||||
Implemented Providers | 4,050 | 4,150 | Above High End | 4,305 | |||||||||||||||||||
Attributed Lives | 1,050,000 | 1,150,000 | Midpoint | 1,120,000 | |||||||||||||||||||
Practice Collections | $ | 2,700 | $ | 2,850 | Midpoint | $ | 2,839.0 | ||||||||||||||||
GAAP Revenue | $ | 1,550 | $ | 1,650 | Mid to High End | $ | 1,657.7 | ||||||||||||||||
Care Margin | $ | 350 | $ | 365 | Mid to High End | $ | 359.2 | ||||||||||||||||
Platform Contribution | $ | 160 | $ | 168 | Above High End | $ | 173.5 | ||||||||||||||||
Adjusted EBITDA d | $ | 70 | $ | 74 | Mid to High End | $ | 72.2 | ||||||||||||||||
c.Management had not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of Gross Profit and Net Income. This is because the Company could not have predicted with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions not within our control as well as certain legal or advisory costs, tax costs or other costs that have arisen. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the directly comparable GAAP measures. d.Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release. |
For the Three Months Ended December 31, | ||||||||||||||||||||
($ in millions, except per share amounts) | 2023 | 2022 | Change (%) | |||||||||||||||||
Total revenue | $ | 440.8 | $ | 364.4 | 21.0 | % | ||||||||||||||
Gross profit | $ | 90.0 | $ | 79.2 | 13.6 | % | ||||||||||||||
Operating income | $ | 1.4 | $ | 2.2 | nm | |||||||||||||||
Net income e | $ | 2.8 | $ | 17.8 | nm | |||||||||||||||
Non-GAAP adjusted net income f | $ | 20.3 | $ | 16.1 | 26.1 | % | ||||||||||||||
Net income per share | $ | 0.02 | $ | 0.14 | nm | |||||||||||||||
Non-GAAP adjusted net income per share | $ | 0.15 | $ | 0.13 | 15.4 | % | ||||||||||||||
e.Net income for the fourth quarter of 2023 included $11.7 million in non-cash stock compensation expense and $2.4 million in legal and other expenses. Net income for the fourth quarter of 2022 included $9.2 million in non-cash stock compensation expense and $1.7 million in legal and other expenses. f.Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release. |
For the Three Months Ended December 31, | ||||||||||||||||||||
($ in millions) | 2023 | 2022 | Change (%) | |||||||||||||||||
Practice Collections | $ | 756.6 | $ | 634.8 | 19.2 | % | ||||||||||||||
Care Margin | $ | 91.5 | $ | 80.1 | 14.2 | % | ||||||||||||||
Platform Contribution | $ | 42.3 | $ | 39.1 | 8.2 | % | ||||||||||||||
Adjusted EBITDA | $ | 17.3 | $ | 14.3 | 21.1 | % | ||||||||||||||
FY 2023 | FY 2024 Guidance g | Y-Y % Change from FY 2023 | |||||||||||||||||||||||||||
($ in millions) | Actual | Low | High | Low | High | ||||||||||||||||||||||||
Implemented Providers | 4,305 | 4,650 | 4,750 | 8.0 | % | 10.3 | % | ||||||||||||||||||||||
Attributed Lives | 1,120,000 | 1,150,000 | 1,200,000 | 2.7 | % | 7.1 | % | ||||||||||||||||||||||
Practice Collections | $ | 2,839.0 | $ | 2,775 | $ | 2,875 | (2.3) | % | 1.3 | % | |||||||||||||||||||
GAAP Revenue | $ | 1,657.7 | $ | 1,600 | $ | 1,675 | (3.5) | % | 1.0 | % | |||||||||||||||||||
Care Margin | $ | 359.2 | $ | 388 | $ | 400 | 8.0 | % | 11.4 | % | |||||||||||||||||||
Platform Contribution | $ | 173.5 | $ | 180 | $ | 188 | 3.8 | % | 8.4 | % | |||||||||||||||||||
Adjusted EBITDA h | $ | 72.2 | $ | 85 | $ | 90 | 17.7 | % | 24.6 | % |
Contact: | ||
Robert Borchert | ||
SVP, Investor & Corporate Communications | ||
IR@priviahealth.com | ||
817.783.4841 |
For the Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
(unaudited) | (unaudited) | (unaudited) | |||||||||||||||||||||
Revenue | $ | 440,828 | $ | 364,424 | $ | 1,657,737 | $ | 1,356,660 | |||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Provider expense | 349,378 | 284,368 | 1,298,573 | 1,051,040 | |||||||||||||||||||
Cost of platform | 52,409 | 43,343 | 197,663 | 170,838 | |||||||||||||||||||
Sales and marketing | 6,249 | 5,173 | 24,732 | 19,741 | |||||||||||||||||||
General and administrative | 29,600 | 28,156 | 109,587 | 129,592 | |||||||||||||||||||
Depreciation and amortization | 1,772 | 1,135 | 6,533 | 4,571 | |||||||||||||||||||
Total operating expenses | 439,408 | 362,175 | 1,637,088 | 1,375,782 | |||||||||||||||||||
Operating income (loss) | 1,420 | 2,249 | 20,649 | (19,122) | |||||||||||||||||||
Interest (income) expense, net | (2,848) | (1,152) | (8,372) | (542) | |||||||||||||||||||
Income (loss) before provision for (benefit from) income taxes | 4,268 | 3,401 | 29,021 | (18,580) | |||||||||||||||||||
Provision for (benefit from) income taxes | 1,944 | (13,447) | 7,993 | (6,516) | |||||||||||||||||||
Net income (loss) | 2,324 | 16,848 | 21,028 | (12,064) | |||||||||||||||||||
Less: Loss attributable to non-controlling interests | (514) | (928) | (2,051) | (3,479) | |||||||||||||||||||
Net income (loss) income attributable to Privia Health Group, Inc. | $ | 2,838 | $ | 17,776 | $ | 23,079 | $ | (8,585) | |||||||||||||||
Net income (loss) income per share attributable to Privia Health Group, Inc. stockholders – basic | $ | 0.02 | $ | 0.16 | $ | 0.20 | $ | (0.08) | |||||||||||||||
Net income (loss) income per share attributable to Privia Health Group, Inc. stockholders – diluted | $ | 0.02 | $ | 0.14 | $ | 0.19 | $ | (0.08) | |||||||||||||||
Weighted average common shares outstanding – basic | 118,109,663 | 114,364,180 | 116,731,406 | 110,695,266 | |||||||||||||||||||
Weighted average common shares outstanding – diluted | 124,831,553 | 124,142,657 | 124,686,067 | 110,695,266 |
December 31, 2023 | December 31, 2022 | ||||||||||
Assets | (unaudited) | ||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 389,511 | $ | 347,992 | |||||||
Accounts receivable | 290,768 | 189,604 | |||||||||
Prepaid expenses and other current assets | 20,525 | 14,366 | |||||||||
Total current assets | 700,804 | 551,962 | |||||||||
Non-current assets: | |||||||||||
Property and equipment, net | 2,325 | 3,386 | |||||||||
Right-of-use asset | 6,612 | 8,089 | |||||||||
Intangible assets, net | 107,630 | 57,387 | |||||||||
Goodwill | 138,749 | 126,938 | |||||||||
Deferred tax asset | 35,200 | 40,368 | |||||||||
Other non-current assets | 8,580 | 4,683 | |||||||||
Total non-current assets | 299,096 | 240,851 | |||||||||
Total assets | $ | 999,900 | $ | 792,813 | |||||||
Liabilities and stockholders’ equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable and accrued expenses | $ | 57,831 | $ | 52,837 | |||||||
Provider liability | 326,078 | 208,424 | |||||||||
Operating lease liabilities, current | 3,043 | 3,013 | |||||||||
Total current liabilities | 386,952 | 264,274 | |||||||||
Non-current liabilities: | |||||||||||
Operating lease liabilities, non-current | 5,246 | 8,490 | |||||||||
Other non-current liabilities | 313 | 1,000 | |||||||||
Total non-current liabilities | 5,559 | 9,490 | |||||||||
Total liabilities | 392,511 | 273,764 | |||||||||
Commitments and contingencies | |||||||||||
Stockholders’ equity: | |||||||||||
Common stock | 1,182 | 1,148 | |||||||||
Additional paid-in capital | 753,869 | 714,639 | |||||||||
Accumulated deficit | (193,614) | (216,693) | |||||||||
Total Privia Health Group, Inc. stockholders’ equity | 561,437 | 499,094 | |||||||||
Non-controlling interest | 45,952 | 19,955 | |||||||||
Total stockholders’ equity | 607,389 | 519,049 | |||||||||
Total liabilities and stockholders’ equity | $ | 999,900 | $ | 792,813 |
For the Years Ended December 31, | |||||||||||
2023 | 2022 | ||||||||||
(unaudited) | |||||||||||
Cash flows from operating activities | |||||||||||
Net income (loss) | $ | 21,028 | $ | (12,064) | |||||||
Adjustments to reconcile loss to net cash provided by operating activities: | |||||||||||
Depreciation | 1,174 | 1,220 | |||||||||
Amortization of intangibles | 5,359 | 3,351 | |||||||||
Amortization of debt issuance costs | — | 687 | |||||||||
Stock-based compensation | 37,098 | 67,359 | |||||||||
Deferred tax expense (benefit) | 7,465 | (7,004) | |||||||||
Changes in asset and liabilities: | |||||||||||
Accounts receivable | (96,877) | (72,202) | |||||||||
Prepaid expenses and other current assets | (6,159) | (5,669) | |||||||||
Other non-current assets and right-of-use asset | (2,418) | 1,383 | |||||||||
Accounts payable and accrued expenses | 4,994 | 6,852 | |||||||||
Provider liability | 113,367 | 67,716 | |||||||||
Operating lease liabilities | (3,214) | (2,433) | |||||||||
Other long-term liabilities | (1,032) | (2,000) | |||||||||
Net cash provided by operating activities | 80,785 | 47,196 | |||||||||
Cash flows from investing activities | |||||||||||
Purchases of property and equipment | (113) | (104) | |||||||||
Business acquisitions, net of cash acquired | (42,858) | — | |||||||||
Net cash used in investing activities | (42,971) | (104) | |||||||||
Cash flows from financing activities | |||||||||||
Repurchase of non-controlling interest | (5,694) | — | |||||||||
Proceeds from non-controlling interest | 659 | 125 | |||||||||
Repayment of note payable | — | (33,250) | |||||||||
Proceeds from exercised stock options | 8,740 | 13,448 | |||||||||
Net cash provided by (used in) financing activities | 3,705 | (19,677) | |||||||||
Net increase in cash and cash equivalents | 41,519 | 27,415 | |||||||||
Cash and cash equivalents at beginning of period | 347,992 | 320,577 | |||||||||
Cash and cash equivalents at end of period | $ | 389,511 | $ | 347,992 | |||||||
Supplemental disclosure of cash flow information: | |||||||||||
Interest paid | $ | 40 | $ | 713 | |||||||
Income taxes paid | $ | 1,040 | $ | 307 | |||||||
For the Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||||||||||
(Dollars in Thousands) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
FFS-patient care | $ | 272,343 | $ | 231,624 | $ | 976,688 | $ | 869,165 | |||||||||||||||
FFS-administrative services | 29,741 | 23,018 | 113,154 | 94,929 | |||||||||||||||||||
Capitated revenue | 85,248 | 57,687 | 338,729 | 218,463 | |||||||||||||||||||
Shared savings | 39,838 | 42,319 | 170,143 | 132,615 | |||||||||||||||||||
Care management fees (PMPM) | 10,615 | 8,023 | 50,519 | 35,541 | |||||||||||||||||||
Other revenue | 3,043 | 1,754 | 8,504 | 5,947 | |||||||||||||||||||
Total Revenue | $ | 440,828 | $ | 364,425 | $ | 1,657,737 | $ | 1,356,660 | |||||||||||||||
December 31, | ||||||||||||||
(Dollars in Thousands) | 2023 | 2022 | ||||||||||||
Balance, beginning of period | $ | 28,617 | $ | — | ||||||||||
Incurred health care costs | ||||||||||||||
Current year | 334,383 | 218,199 | ||||||||||||
Prior years | 2,436 | — | ||||||||||||
Total claims incurred | $ | 336,819 | $ | 218,199 | ||||||||||
Claims Paid | ||||||||||||||
Current year | $ | (270,810) | $ | (189,582) | ||||||||||
Prior years | (27,488) | — | ||||||||||||
Total claims paid | $ | (298,298) | $ | (189,582) | ||||||||||
Balance, end of period | $ | 67,138 | $ | 28,617 |
For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||||||||||||
(unaudited; $ in millions) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
Implemented Providers(n) | 4,305 | 3,606 | 4,305 | 3,606 | ||||||||||||||||||||||
Attributed Lives(o) | 1,120,000 | 856,000 | 1,120,000 | 856,000 | ||||||||||||||||||||||
Practice Collections(p) | $ | 756.6 | $ | 634.8 | $ | 2,839.0 | $ | 2,424.1 | ||||||||||||||||||
(m) Any slight variations in totals are due to rounding. | ||||||||||||||||||||||||||
(n) Implemented Providers is defined as the total of all service professionals on Privia Health’s platform at the end of a given period who are credentialed by Privia Health and billed for medical services, in both Owned and Non-Owned Medical Groups during that period. | ||||||||||||||||||||||||||
(o) Attributed Lives are defined as any patient that a payer deems attributed to Privia to deliver care as part of a value-based care arrangement through a provider of primary care services as of the end of a particular period. | ||||||||||||||||||||||||||
(p) Practice Collections are defined as the total collections from all practices in all markets and all sources of reimbursement that the Company receives for delivering care and providing Privia Health’s platform and associated services. Practice Collections differ from revenue by including collections from Non-Owned Medical Groups. |
For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||||||||||||
(unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
Care Margin | $ | 91,450 | $ | 80,056 | $ | 359,164 | $ | 305,620 | ||||||||||||||||||
Platform Contribution | $ | 42,282 | $ | 39,089 | $ | 173,481 | $ | 148,540 | ||||||||||||||||||
Platform Contribution Margin | 46.2% | 48.8% | 48.3% | 48.6% | ||||||||||||||||||||||
Adjusted EBITDA | $ | 17,279 | $ | 14,265 | $ | 72,228 | $ | 60,852 | ||||||||||||||||||
Adjusted EBITDA Margin | 18.9% | 17.8% | 20.1% | 19.9% | ||||||||||||||||||||||
(q) In addition to results reported in accordance with GAAP, Privia Health discloses Care Margin, Platform Contribution, Platform Contribution margin, Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. Each are defined as follows: •Care Margin is Gross Profit excluding amortization of intangible assets. •Platform Contribution is Gross Profit, excluding amortization of intangible assets, less Cost of platform and excluding stock-based compensation expense included in Cost of platform. •Platform Contribution margin is Platform Contribution divided by Care Margin. •Adjusted EBITDA is net income (loss) attributable to Privia Health Group, Inc. shareholders and subsidiaries excluding non-controlling interests, provision for (benefit from) income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation, employer taxes on equity vesting/exercises, severance charges and other nonrecurring expenses. •Adjusted EBITDA Margin is Adjusted EBITDA divided by Care Margin. | ||||||||||||||||||||||||||
(r) Any slight variations in totals are due to rounding. |
For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||||||||||||
(unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
Revenue | $ | 440,828 | $ | 364,424 | $ | 1,657,737 | $ | 1,356,660 | ||||||||||||||||||
Provider expense | (349,378) | (284,368) | (1,298,573) | (1,051,040) | ||||||||||||||||||||||
Amortization of intangible assets | (1,477) | (842) | (5,359) | (3,351) | ||||||||||||||||||||||
Gross Profit | $ | 89,973 | $ | 79,214 | $ | 353,805 | $ | 302,269 | ||||||||||||||||||
Amortization of intangible assets | 1,477 | 842 | 5,359 | 3,351 | ||||||||||||||||||||||
Care margin | $ | 91,450 | $ | 80,056 | $ | 359,164 | $ | 305,620 | ||||||||||||||||||
(s) Any slight variations in totals are due to rounding. |
For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||||||||||||
(unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
Revenue | $ | 440,828 | $ | 364,424 | $ | 1,657,737 | $ | 1,356,660 | ||||||||||||||||||
Provider expense | (349,378) | (284,368) | (1,298,573) | (1,051,040) | ||||||||||||||||||||||
Amortization of intangible assets | (1,477) | (842) | (5,359) | (3,351) | ||||||||||||||||||||||
Gross Profit | 89,973 | 79,214 | 353,805 | 302,269 | ||||||||||||||||||||||
Amortization of intangible assets | 1,477 | 842 | 5,359 | 3,351 | ||||||||||||||||||||||
Cost of platform | (52,409) | (43,343) | (197,663) | (170,838) | ||||||||||||||||||||||
Stock-based compensation(u) | 3,241 | 2,376 | 11,980 | 13,758 | ||||||||||||||||||||||
Platform Contribution | $ | 42,282 | $ | 39,089 | $ | 173,481 | $ | 148,540 | ||||||||||||||||||
(t) Any slight variations in totals are due to rounding. | ||||||||||||||||||||||||||
(u) Amount represents stock-based compensation expense included under Cost of Platform. |
For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||||||||||||
(unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
Net income (loss) | $ | 2,838 | $ | 17,776 | $ | 23,079 | $ | (8,585) | ||||||||||||||||||
Net (loss) attributable to non-controlling interests | (514) | (928) | (2,051) | (3,479) | ||||||||||||||||||||||
Provision for (benefit from) income taxes | 1,944 | (13,447) | 7,993 | (6,516) | ||||||||||||||||||||||
Interest expense | (2,848) | (1,152) | (8,372) | (542) | ||||||||||||||||||||||
Depreciation and amortization | 1,772 | 1,135 | 6,533 | 4,571 | ||||||||||||||||||||||
Stock-based compensation | 11,669 | 9,175 | 37,098 | 67,359 | ||||||||||||||||||||||
Other expenses(w) | 2,418 | 1,706 | 7,948 | 8,044 | ||||||||||||||||||||||
Adjusted EBITDA | $ | 17,279 | $ | 14,265 | $ | 72,228 | $ | 60,852 | ||||||||||||||||||
(v) Any slight variations in totals are due to rounding. | ||||||||||||||||||||||||||
(w) Other expenses include employer taxes on equity vesting/exercises, legal, severance and certain non-recurring costs. Employer taxes on equity vesting/exercises of $1.6 million and $3.2 million were recorded for the years ended December 31, 2023 and 2022, respectively. |
For the Three Months Ended December 31, | For the Years Ended December 31, | ||||||||||||||||||||||
(unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
Net income (loss) | $ | 2,838 | $ | 17,776 | $ | 23,079 | $ | (8,585) | |||||||||||||||
Stock-based compensation | 11,669 | 9,175 | 37,098 | 67,359 | |||||||||||||||||||
Intangible amortization expense | 1,477 | 842 | 5,359 | 3,351 | |||||||||||||||||||
Provision for (benefit from) income tax | 1,944 | (13,447) | 7,993 | (6,516) | |||||||||||||||||||
Other expenses(y) | 2,418 | 1,706 | 7,948 | 8,044 | |||||||||||||||||||
Adjusted net income attributable to Privia Health Group, Inc. | $ | 20,346 | $ | 16,052 | $ | 81,477 | $ | 63,653 | |||||||||||||||
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic | $ | 0.16 | $ | 0.14 | $ | 0.69 | $ | 0.58 | |||||||||||||||
Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted | $ | 0.15 | $ | 0.13 | $ | 0.64 | $ | 0.52 | |||||||||||||||
Weighted average common shares outstanding – basic | 118,109,663 | 114,364,180 | 116,731,406 | 110,695,266 | |||||||||||||||||||
Weighted average common shares outstanding – diluted | 124,924,442 | 124,142,657 | 125,084,821 | 122,952,853 | |||||||||||||||||||
(x) Any slight variations in totals due to rounding. | |||||||||||||||||||||||
(y) Other expenses include employer taxes on equity vesting/exercises, legal, severance and certain non-recurring costs. Employer taxes on equity vesting/exercises of $1.6 million and $3.2 million were recorded for the years ended December 31, 2023 and 2022, respectively. |
Cover |
Feb. 27, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Feb. 27, 2024 |
Entity Registrant Name | Privia Health Group, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-40365 |
Entity Tax Identification Number | 81-3599420 |
Entity Address, Address Line One | 950 N. Glebe Rd., |
Entity Address, Address Line Two | Suite 700 |
Entity Address, State or Province | VA |
Entity Address, City or Town | Arlington, |
Entity Address, Postal Zip Code | 22203 |
City Area Code | 571 |
Local Phone Number | 366-8850 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.01 par value per share |
Trading Symbol | PRVA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001759655 |
Amendment Flag | false |
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end
!)5)H^XAET(?X=8HD!RY"E>?$V=M3@Y=U7(Q8S%-E83_VJ6E=.OXI.%^*N
M\N.E#TK65D#OSE+FBRXMHMQ[2:@H.V4#B*'I+$JP>0)_%[;V8'\58?Y [N#Y
ML.3O7EKN-?O*4C_,<"T9 TN+VRH^P."6B>TG^00> ;N%110IKU(OER852V,T
MO%#ZZU=J21/I)JRX"6EONBT]JKG"FO_N&K,+&;*LKX%OZ=_VS$N>OT(T4>#U
M01IB:$5 >*N,60Z=;5Z:'MU)XQ,#I>B'43BW>5?<%B#R+75!)UWZ\P^JS<[?
M5^/X0;6&HPZ]82/]%!J84.JHAFG+Q ;VI;H70,3*? V3TM-!.Y/Q<,IN?("<":&2O1[XR^E]*;/8XF[YT!
M536]V]!>R*?I=Y6]X\L\8R+O,.]J]A.:;R4NY[\;9/\[S#QKC+;7_*I[&FU>
M-090G4_-!GV;R_<+E5U%R=7O67J77YO%YX8E#W,4,D&$ZP$>A!P0!'W >2
M9QZ76+E^*)A=;]DXSM06AW6GM,'JK, Z:[2V?64SM5W;RL&$C=-5VG+5HZ7<
MR<2 CK+9[\@-Y<[@MOO)W>:#V\EJ=Z.#^=L.>
MC>3/U$(>I'<0/4Y!F$8OG
M1 2*(=,->IXTDM?*+/N(< "1\GQ) @V]SLO^MONI2?T)H;.!:'&GY#9[^X4]
MC),C"]JKL[)5NC[G>OY+:[\>Z6; VE=K]DNU6/=J_81 +]&D"U_FMI8.Y'.4UX@LE%9+[^LL/Y
M;V*KCMDU>R9IC^(@F@!?+1[I163.F"<[LCFTV91E;:QM1+>%R,Y,B.?O]GA1
M\PT([*;O"Y8DV?_>PWQV+JRKA4:M;)$+D[P+6)^1KF\>KW>@'CY4W^GR171Q
M
)-$%\=Y
M0^*!K9IL$=;ZCKC&M:#*9^M-1OTH.$JV2>QMA;8LNO'OQ&I>8::XD>7Z 23H
MW9##FYF8?3@\N(3V671I-6:?A9OWFI3>P236JFUB.WTE(:8FP0EX@:#I@2(]
M&7F?CLE_0*/8)*:"W-(@923&^TO#3:4\#YZ/E83:0*7U)/IFZ9-)'RU\IL2I
M%1I7W=^;3XSY[9#_/&+KA9 G/SZYA:LK@^\;W2C?%K--C@6*!4S$"YKX]#-Y
M%T1@E(,5&8 =23Y0\8G)A_,D:^/,